Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

A Dilutive Offering In The Offing? Oppenheimer Downgrades Synergy Pharma

Courtesy of Benzinga.

A Dilutive Offering In The Offing? Oppenheimer Downgrades Synergy Pharma

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced an offering of 21 million shares of its common stock at $2.58 per share in November, and at least one Wall Street analyst said another dilutive offering is imminent.

The Analyst

Oppenheimer’s Derek Archila downgraded Synergy Pharmaceuticals’ stock rating from Outperform to Perform with no assigned price target.

The Thesis

Synergy’s Trulance therapy for constipation is a differentiated product and is likely to gain traction in the market, Archila said in the downgrade note. (See the analyst’s track record here.) 

At the same time, Synergy is unlikely to quality for a third and fourth tranch of funding from the health care-focused investment firm CRG, which previously offered non-dilutive financing to the company, according to Oppenheimer. 

As part of the financing deal with CRG, Synergy needs to hold at least $128 million in cash on Jan. 31, 2018 to quality for the next tranche of $100 million, the analyst said. But based on the analyst’s spend estimates for Opex, there is “some risk to whether or not” the company will meet the $128-million cash target that looms in a few weeks.

Synery’s cost-reduction program, which was detailed during the third-quarter conference call, is unlikely to be sufficient to generate enough savings to eliminate the need for an additional stock raise, the analyst said.

“While we could be wrong, another equity raise seems most logical, either alone or potentially in conjunction with an acquisition to add another product to sales reps’ bag,” Archila said. “Debt seems less likely, given the terms of the CRG deal though there is always the possibility of renegotiation. We view U.S. licensing/ partnership/royalty deals as less beneficial to equity holders.”

Price Action

Shares of Synergy Pharmaceuticals were down 11.68 percent Friday afternoon at $2.15.

Related Links:

Attention Biotech Investors: Brace For These January PDUFA Events

Thoughts On Synergy Pharma’s Valuation As Cantor Initiates At Overweight

Latest Ratings for SGYP

Date Firm Action From To
Jan 2018 Oppenheimer Downgrades Outperform Perform
Sep 2017 Citigroup Maintains Sell
Jun 2017 Cantor Fitzgerald Initiates Coverage On Overweight

View More Analyst Ratings for SGYP


View the Latest Analyst Ratings

Posted-In: Derek Archilla Oppenheimer pharmaAnalyst Color Downgrades Health Care Analyst Ratings General Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!